Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
| Revenue (TTM) | $46.59B |
| Gross Profit (TTM) | $26.48B |
| EBITDA | $11.68B |
| Operating Margin | 14.70% |
| Return on Equity | 10.60% |
| Return on Assets | 5.33% |
| Revenue/Share (TTM) | $26.76 |
| Book Value | $29.54 |
| Price-to-Book | 3.50 |
| Price-to-Sales (TTM) | 3.92 |
| EV/Revenue | 4.424 |
| EV/EBITDA | 17.58 |
| Quarterly Earnings Growth (YoY) | -47.50% |
| Quarterly Revenue Growth (YoY) | 13.00% |
| Shares Outstanding | $1.73B |
| Float | $1.72B |
| % Insiders | 0.49% |
| % Institutions | 81.85% |
Volatility is currently expanding
Schwab US Dividend Equity ETF has outperformed SPY YTD, up over 25% versus SPY's ~12%. SCHD's top holdings, including DINO, APA, and TXN, have delivered strong double- and triple-digit returns, driving ETF performance. Dividend growth remains robust, with eight SCHD constituents announcing increases averaging 5.73%, supporting the ETF's income appeal.
Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and global pandemics.
Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. In the first part of the year before we invested, Abbott slightly missed earnings estimates while it was digesting its acquisition of Exact Sciences, along with a variety of turmoil in the medtech and infant nutrition industries. Digital and print publisher People Inc. was a detractor in the quarter, while hospitality and entertainment company MGM Resorts also detracted.
Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choosing the wrong one in retirement could cost you more than you expect.
The market is regaining confidence in Avantor's ability to grow organically and in Emmanuel Ligner's turnaround plan. Biopharma company Regeneron reported a solid set of results, with key drug Dupixent continuing to outpace our and the market's growth expectations. Building products company Fortune Brands Innovations saw its stock price decline in Q3, retracing Q2's positive move related to excitement over Jesse Singh's appointment as CEO.
ABT's Q3 earnings are likely to have benefited from Diagnostics growth, Medical Device momentum and Nutrition innovations, while its valuation below historical levels draw investor interest.
Abbott (ABT) closed the most recent trading day at $101.82, moving +2.23% from the previous trading session.
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABT and any ticker you trade — then tracks every position and per-strategy win rate.
